Close
Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

Technological Innovation Program (TIP): NIST proposes new program support, promote, and accelerate innovation in the United States through high-risk, high-reward research in areas of critical national need.

BIO applauds NIST on implementation of TIP program and urges that personalized medicine be included as an area of "critical national need"

Cures Acceleration Network: BIO Strongly Supports the CAN Program

Implementation of CAN will help NIH-funded researchers bridge the precarious gap between basic research and the eventual development of new cures and treatments for many of the diseases we face today.

Cures Acceleration Network: Patient Group Letter

The letter, signed by approximately 85 patient groups, requests appropriation for CAN in FY2011

IFRS Roadmap: SEC requests comments on U.S. conversion to a set of global accounting standards

BIO provides comment letter to SEC generally supporting the IFRS roadmap while maintaining safeguards for emerging companies during transition.

Pilot Circuit Breaker Proposal: SEC issues proposal on pilot circuit breaker program to combat abusive short selling

BIO commends the SEC on its pilot circuit breaker proposal and urges the use of biotech companies in such proposal

Sarbanes-Oxley in Financial Services Compromise: Sarbanes-Oxley 404(b) Legislative Text in the Wall Street Reform and Consumer Protection Act of 2009

BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies.

Sarbanes Oxley 404(b) recommendations made by the 2009 Government-Business Forum on Small Business Capital Formation

...

Letter to the Honorable John Carey

Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.

Letter to Governor Deval Patrick

BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.

BIO Testimony regarding Oregan Senate Bill 570

Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.